Appili Therapeutics Inc Class A (APLI) AI Stock Analysis

• Market Cap: C$4.85M
• Dividend Yield: N/A
• Average Volume (3M): 71.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.23
• Revenue Growth: -89.15%
• EPS Growth: 25.91%
• Country: CA
• Employees: 8
• Sector: Healthcare
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 121,266,120
• 10 Day Avg. Volume: 85,713
• 30 Day Avg. Volume: 71,779
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 34.02
• Price to Cash Flow (P/CF): -2.40
• P/FCF Ratio: 13.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Appili Therapeutics is currently facing significant financial difficulties, with declining revenues, high leverage, and negative equity. While technical indicators are neutral, the company's valuation is weak, reflecting ongoing losses and no dividends. Recent corporate events, including U.S. federal funding proposals and pipeline advancements, provide some optimism for future improvements, but the overall financial health remains a critical concern.

Appili Therapeutics Inc Class A Business Overview & Revenue Model

Company Description

Appili Therapeutics Inc Class A (APLI) is a biopharmaceutical company focused on the development of novel therapies for infectious diseases and other unmet medical needs. The company leverages its expertise in drug development to advance a diverse pipeline of innovative products, including vaccines, treatments for infectious diseases, and other therapeutics. Appili's strategy involves identifying and developing promising candidates that address significant healthcare challenges, aiming to improve patient outcomes and contribute to public health.

How the Company Makes Money

Appili Therapeutics Inc primarily generates revenue through partnerships, collaborations, and licensing agreements with other pharmaceutical companies and research institutions. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development goals, and royalties on sales of successfully commercialized products. Additionally, the company may receive government grants or funding from non-profit organizations to support its research and development activities, particularly for projects that align with public health priorities. Appili's revenue model is heavily reliant on the successful advancement and commercialization of its pipeline candidates, as well as strategic alliances that leverage its expertise and resources.

Appili Therapeutics Inc Class A Financial Statement Overview

Summary

Appili Therapeutics is facing significant financial challenges, with declining revenues and profitability, high leverage, and negative equity. Cash flow remains under pressure with continued negative free cash flow. The company needs strategic improvements to stabilize its financial position and return to growth.

Income Statement

The company shows declining revenue with a significant decrease from $1.39M in 2022 to $124.7K in TTM (Trailing-Twelve-Months) 2024. Gross profit margin remains relatively high at 94.72% for TTM 2024, but the net and EBIT margins are severely negative due to high operational losses. The revenue growth rate is negative, indicating a contraction in business activities.

Balance Sheet

The balance sheet is concerning with negative stockholders' equity of -$13.63M in TTM 2024, indicating liabilities exceed assets. The debt-to-equity ratio cannot be calculated due to negative equity, highlighting financial instability. The equity ratio is negative due to the large accumulated deficit.

Cash Flow

The company exhibits negative free cash flow consistent with its net losses, with a minor reduction in negative free cash flow from 2023 to TTM 2024. Operating cash flow is negative, indicating cash outflows from core operations. There is an absence of free cash flow growth, reflecting ongoing challenges in generating cash.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
124.75K	827.41K	334.18K	1.39M	0.00	199.11K
	Gross Profit
118.16K	827.41K	327.91K	1.39M	-14.84K	199.11K
	EBIT
-2.42M	-8.05M	-7.91M	-24.68M	-16.30M	-6.13M
	EBITDA
-1.28M	-2.10M	-8.19M	-24.31M	-14.87M	-5.63M
	Net Income Common Stockholders
-3.96M	-3.78M	-9.24M	-25.12M	-14.33M	-5.42M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
186.17K	94.49K	2.47M	6.66M	16.12M	10.54M
	Total Assets
2.09M	1.49M	3.13M	8.28M	18.32M	11.17M
	Total Debt
11.28M	8.18M	7.67M	4.98M	1.03M	1.00M
	Net Debt
11.10M	8.09M	5.20M	-1.69M	-10.03M	-9.50M
	Total Liabilities
15.72M	12.42M	10.53M	11.55M	5.56M	2.33M
	Stockholders Equity
-13.63M	-10.92M	-7.40M	-3.27M	12.75M	8.85M
Cash Flow		Free Cash Flow
-641.51K	-2.49M	-10.10M	-19.08M	-11.46M	-4.26M
	Operating Cash Flow
-639.15K	-2.46M	-10.10M	-19.08M	-11.45M	-4.26M
	Investing Cash Flow
-1.71K	-29.06K	-3.17K	5.06M	-4.99M	-1.14K
	Financing Cash Flow
220.56K	122.05K	5.91M	9.56M	17.02M	9.36M

Appili Therapeutics Inc Class A Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:APLI, the sentiment is Neutral. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.03, and above the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 48.42 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:APLI.

Appili Therapeutics Inc Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
THX	75 Outperform	C$310.91M	4.19	40.38%	―	-5.98%	81.04%
MBX	70 Outperform	C$58.08M	29.93	6.85%	―	2.72%	-47.79%
DRT	56 Neutral	$197.21M	12.22	59.45%	―	-2.68%	―
Sector *	48 Neutral	$6.84B	1.02	-53.11%	2.50%	16.84%	0.92%
APLI	42 Neutral	C$4.85M	―	34.61%	―	-89.15%	25.91%

Appili Therapeutics Inc Class A Corporate Events

Appili Therapeutics Seeks $117.5 Million in Federal Funding for Infectious Disease Treatments

Appili Therapeutics announced the submission of four new U.S. federal funding proposals totaling $117.5 million, aimed at advancing treatments for infectious diseases. The company also updated its transaction with Aditxt and extended the deadline for its going-private transaction. Appili’s strategic moves, including joining the Medical CBRN Defense Consortium, highlight its commitment to U.S. biodefense and preparedness, positioning it as a key player in developing medical countermeasures.

Appili Therapeutics Advances Pipeline with Strong Shareholder and Government Support

Appili Therapeutics reported its third-quarter fiscal results, highlighting significant shareholder support for a take-private transaction with Aditxt and progress in its key pipeline programs. The company is advancing ATI-1701, a biodefense vaccine candidate with substantial U.S. government backing, and ATI-1801, a topical antiparasitic product with FDA alignment on development requirements. Additionally, Appili has launched LIKMEZ™, an FDA-approved liquid formulation of metronidazole, in partnership with Saptalis Pharmaceuticals, addressing challenges in oral drug compliance.